Literature DB >> 12927928

Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression.

Harry L A Janssen1, Hajime Higuchi, Ahmad Abdulkarim, Gregory J Gores.   

Abstract

BACKGROUND/AIMS: Apoptosis by death receptors, such as Fas and tumor necrosis factor (TNF)-alpha receptor-1, play a significant role in the pathogenesis of hepatitis B virus (HBV)-infections. Although liver also expresses death receptors for TNF-related apoptosis-inducing ligand (TRAIL), information is lacking regarding the effects of HBV on apoptosis by TRAIL. Thus, the aims of this study were to examine the effects of HBV replication on TRAIL cytotoxicity.
METHODS: Hep G2 and Hep G2.215 cells, the latter which is stably transfected with HBV, were employed for these studies.
RESULTS: TRAIL-mediated cell killing was concentration-dependent and greater in Hep G2.2.15 cells at all doses as compared to the parent cell line, Hep G2 cells. Cell death by apoptosis was confirmed by demonstrating caspase activation and inhibition of cell killing by a caspase inhibitor, zVAD-fmk. TRAIL-R1/DR4 protein expression was enhanced in Hep G2.2.15 cells as compared to Hep G2 cells. Lamivudine treatment reduced TRAIL-mediated apoptosis and TRAIL-R1/DR4 expression in Hep G2.2.15 cells. In Hep G2 cells transfected with the HBV-encoded X antigen (HBxAg), sensitivity to TRAIL-mediated apoptosis and TRAIL-R1/DR4 expression were both increased.
CONCLUSIONS: TRAIL-induced apoptosis is enhanced by the level of HBV replication in human hepatocytes, in part, by HBxAg-dependent upregulation of TRAIL-R1/DR4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927928     DOI: 10.1016/s0168-8278(03)00265-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

Review 1.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver.

Authors:  S C Afford; D H Adams
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

2.  Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B.

Authors:  Gong-Ying Chen; Jian-Qin He; Guo-Cai Lu; Ming-Wei Li; Chen-Huai Xu; Wei-Wei Fan; Chen Zhou; Zhi Chen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein.

Authors:  Brian D Poole; Jing Zhou; Amy Grote; Adam Schiffenbauer; Stanley J Naides
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

5.  Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.

Authors:  Harmeet Malhi; Fernando J Barreyro; Hajime Isomoto; Steven F Bronk; Gregory J Gores
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

6.  Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis.

Authors:  Yan Liang; Zaixing Yang; Chang Li; Ye Zhu; Lingzhen Zhang; Renqian Zhong
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

Review 7.  Immune cell-mediated liver injury.

Authors:  Nadia Corazza; Anastasia Badmann; Christoph Lauer
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

Review 8.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 9.  Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature.

Authors:  Takeshi Kuroda; Yoko Wada; Daisuke Kobayashi; Hiroe Sato; Syuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

10.  HIV induces TRAIL sensitivity in hepatocytes.

Authors:  Challagundla K Babu; Kanitta Suwansrinon; Gary D Bren; Andrew D Badley; Stacey A Rizza
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.